期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

三氧化二砷对MRL-lpr小鼠自身免疫反应及与凋亡相关的Caspase家族的影响

Effects of Arsenic Trioxide on Autoimmunity and Caspase Family Related to Apoptosis in MRL-lpr Mice
下载PDF
导出
摘要 目的:探讨三氧化二砷对MRL-lpr小鼠自身免疫反应及与凋亡相关的caspase家族的影响。方法:14只MRL-lpr小鼠,随机分为两组,实验组用三氧化二砷隔日腹腔注射,对照组用生理盐水,疗程结束后检测两组小鼠尿蛋白、抗双链DNA抗体、肾脏免疫球蛋白G沉积情况的变化及caspase-3表达情况和caspase-8活性变化。结果:实验组尿蛋白、抗双链DNA抗体水平均低于对照组,肾脏免疫球蛋白G沉积亦少于对照组;实验组caspase-3表达增多,caspase-8活性增强。结论:三氧化二砷对MRL-lpr小鼠自身免疫反应具有抑制作用,且这种抑制作用与其激活caspase家族成员,诱导淋巴细胞凋亡有关。 Objective：To investigate the effects of arsenic trioxide on autoimmunity and caspase family related to apoptosis in MRL - lpr mice. Methods： Fourteen MRL - lpr mice were randomly assigned into experimental group or control group. Mice in experimental group were treated with arsenic trioxide and thcxse in control group with saline. Proteinuria, anti - dsDNA antibody and IgG deposition in kidneys were detected after 55 days. Caspase - 3 expression and caspase - 8 activity of spleen lymphocytes in MRL lpr mice were measured at the same time. Results：The concentrations of proteinuria and anti - dsDNA antibody in experimental group were significantly lower than those in control group. There was less IgG deposition in kidneys in experimental group. After arsenic trioxide treatment, more caspase - 3 expressed and activity of caspase - 8 increased. Conclusion：Arsenic trioxide can suppress the autoimmunity in MRL- lpr mice, which may be related to activated easpase and lymphocyte apoptosis induced by arsenic trioxide.
作者 刘睿婵 王明奡 殷恒强 贾西贝 解汝娟
机构地区 哈尔滨医科大学附属第一临床医院肾内科
出处 《中国中西医结合肾病杂志》 2009年第10期859-862,I0002,共5页 Chinese Journal of Integrated Traditional and Western Nephrology
基金 黑龙江省教育厅基金资助项目(No.11521084) 黑龙江省卫生厅基金资助项目(No.2005-148) 哈尔滨医科大学附属第一临床医学院青年基金资助项目(No.2007103)
关键词 三氧化二砷 凋亡 Caspase-3 CASPASE-8 Arsenic trioxide Apoptosis Caspase- 3 Caspase - 8
分类号 R593.241 [医药卫生—内科学]
  • 相关文献

参考文献19

  • 1Lenardo M,Chan KM, Homung F, et al. Mature T lymphocyte apoptosis- immune regulation in a dynamic and unpredictable antigenic environment. Annu Rev Immunol, 1999,17:221 - 253.
  • 2Krueger A, Fas SC, Baumann S, et al. The role of CD95 in the regulation of peripheral T - cell apoptosis, Immunol Rev, 2003, 193: 58 - 69.
  • 3Zhang TD, Chen GQ, Wang ZG, et al. Arsenic trioxide, a therapeutic agent for APL. Oneogene,2001,20(49) :7146- 7153.
  • 4de The H, Chelbi - Alix MK. APL, a model disease for cancer therapies? Oncogene, 2001,20 ( 49 ) : 7136 - 7139.
  • 5Chelbi- Alix MK, Bobe P, Benoit G, et al. Arsenic enhances the aetivation of Statl by interferon leading to synergistic expression of IRF- 1. Oncogene,2003,22(57) :9121 - 9130.
  • 6Miller W H Jr, Schipper HM, Lee J S, et al. Mechanisms of action of arsenic trioxide. Cancer Res, 2002,62(14) : 3893 - 3903.
  • 7崔极贵,徐宏.狼疮性肾炎的发病机制及治疗研究进展[J].中国中西医结合肾病杂志,2008,9(7):649-652. 被引量：10
  • 8Santiago - Raber ML, Laporte C, Reininger L, et al. Genetic basis of routine lupus. Autoimmun Rev, 2004,3( 1 ) : 33 - 39.
  • 9Bobe P, Bonardelle D, Benihoud K, et al. Arsenic trioxide: a promising novel therapeutic agent for lymphoproliferative and autoimmune syndromes in MRL/lpr mice. Blood, 2006, 108 (13) :3967 - 3975.
  • 10Creagh EM, Conroy H, Martin SJ. Caspase - activation pathways in apoptosis and immunity. Immunol Rev, 2003,193 : 10 - 21.

二级参考文献24

  • 1Doria A, Laccarino L, Ghirardello A, et al. Long - term prognosis and Causes of death in systemic lupus erythematosus, Am Med, 2006,90( 1 ) : 15 - 19.
  • 2Ponticelli C. Systemic lupus erythematosus(Clinical). In: Davison AM ed. Oxford Textbook of clinic Nephrology. 2nd ed. oxford: Univerxity press, 1998. 935.
  • 3Hill GS, Hinglais N, Tron F, et al. Systemic lupus erythematosus. Morphologic Correlation with immunologic and clinical data at the time of biopsy. Am J Med, 1978,64( 1 ) :61 - 79.
  • 4Mohan C,Data SK. Lups: Key pathogenic mechanisms and contributing factors. Clin Immunol Immunopathol, 1995, 77 ( 3 ) : 209-220.
  • 5Hochberg MC, Perlmutter DL, Medsger TA, et al. Prevalence of self-reported physician - diagnosed systemic lupus erythematosus in the USA. Lupus, 1995,4(6) :454 -456.
  • 6Kono DH, Theofilopoulos AN. The genetics of murine systemic lupus erythematosus. In: wallace Dj, Hahn BH, eds. Bubois, lupus erythematos. Baltimore; williams &wilkins, 1997.119 - 132.
  • 7Schur PH, Kammer GM. Treatment of systemic lupus erythernatosus, In: Tsokos GC, modem Therapeutics in Rheumatic Diseases. Totowa: Hamana press, 2001. 259 295.
  • 8No authors listed. Guilddine for referral and management of systemic lupus erythematosus in adults. American College of Rheumatology Ad Hoc Committee on Systemic lupus Erythernatosus guidelines. Arthritis Rheum, 1999, 42 ( 9 ) : 1785 - 1796.
  • 9Urowiz MB, Bookman AA. The bimodal mortality pattern of systemic lupus exythematosus. Am J Med, 1976,60 (2) : 221 - 225.
  • 10Edwards JC, Snaith ML. A double blind controlled trial of methylprednisolone infusions in systemic lupus erythematosus using individualised outcome assesment. Ann Rheum Dis, 1987,46(10) : 773 - 776.

共引文献9

中国中西医结合肾病杂志
2009年 第10期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部